OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA

被引：0
|
作者：
Detke, Holland C. [1 ]
Weiden, Peter J. [2 ]
Llorca, P. M. [3 ]
Choukour, M. [4 ]
Watson, Susan B. [1 ]
Brunner, E. [1 ]
Ascher-Svanum, H. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[3] Ctr Hosp Univ, Psychiat Serv, Clermont Ferrand, France
[4] i3 Statprobe, Med Writing & Sci Commun, San Diego, CA USA
来源：
SCHIZOPHRENIA BULLETIN | 2011年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：300 / 300
页数：1
相关论文
共 50 条
  • [1] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [2] Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study
    Detke, H.
    Weiden, P. J.
    Lambert, T.
    Llorca, P. M.
    Choukour, M.
    Watson, S. B.
    Brunner, E.
    Ascher-Svanum, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S464 - S464
  • [3] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, D.
    Ascher-Svanum, H.
    Bertsch, J.
    Detke, H.
    Mcdonnell, D.
    Witte, M.
    Haro, J.
    VALUE IN HEALTH, 2011, 14 (07) : A288 - A289
  • [4] RISK OF RELAPSE AND HOSPITALIZATION IN THE 2-YEAR OPEN-LABEL TREATMENT OF OUTPATIENTS WITH SCHIZOPHRENIA RANDOMIZED TO OLANZAPINE LONG-ACTING INJECTION OR ORAL OLANZAPINE
    Novick, Diego
    Ascher-Svanum, Haya
    Bertsch, Jordan
    Detke, Holland C.
    McDonnell, David
    Maria Haro, Josep
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S357 - S357
  • [5] Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
    Ascher-Svanum, Haya
    Novick, Diego
    Maria Haro, Josep
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1125 - 1131
  • [6] LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION
    Ascher-Svanum, Haya
    Novick, Diego
    Haro, Josep M.
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S165 - S165
  • [7] Switching forensic schizophrenia outpatients from long-acting injectable antipsychotics to olanzapine: An open-label naturalistic study
    Bourget, D
    Labelle, A
    Boulay, LJ
    Tessier, P
    Ellis, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 160 - 161
  • [8] Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: An open-label naturalistic pilot study
    Labelle, A
    Bourget, D
    Boulay, LJ
    Ellis, J
    Tessier, P
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) : 545 - 553
  • [9] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    McDonnell, David P.
    Kryzhanovskaya, Ludmila A.
    Zhao, Fangyi
    Detke, Holland C.
    Feldman, Peter D.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (06) : 422 - 433
  • [10] Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation
    Gulliver, A.
    McDonnell, D. P.
    Kryzhanovskaya, L. A.
    Zhao, F.
    Detke, H. C.
    Feldman, P. D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 152
12345